Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes
New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions
In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide
Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension
Login to comment